Table 2. Main characteristics of the eligible studies that included clinicopathological features.
| Study | Tumor Type | Sample size | Test Method | Cut-off | Co-variants |
|---|---|---|---|---|---|
| Shi 2013 | NSCLC | 72 | qRT-PCR | NA | LNM; gender; differentiation; tumor size |
| Cao 2014 | CC | 102 | qRT-PCR | median value | LNM; differentiation |
| Sun 2014 | GC | 89 | qRT-PCR | median value | LNM; DM; differentiation; gender; tumor size; clinical stage |
| Tu 2014 | HCC | 71 | qRT-PCR | mean value | LNM; gender; tumor size; clinical stage; age |
| Yin 2014 | CRC | 66 | qRT-PCR | mean value | LNM; DM; gender; age |
| Chang 2015 | HCC | 50 | qRT-PCR | mean value | Differentiation; gender; tumor size |
| Dong 2015 | NSCLC | 72 | qRT-PCR | mean ratio | LNM; DM; differentiation; gender; clinical stage; age |
| Gao 2015 | OC | 60 | qRT-PCR | NA | LNM; differentiation |
| Hu 2016 | HCC | 32 | qRT-PCR | mean value | Gender; clinical stage |
| Li 2016 | OC | 63 | qRT-PCR | median ratio | LNM; DM; differentiation; tumor size; clinical stage |
| Meng 2016 | GC | 55 | qRT-PCR | NA | LNM; differentiation; gender; age; tumor size; clinical stage |
| Wu 2016 | NSCLC | 48 | qRT-PCR | NA | LNM; differentiation; gender |
| Xue 2016 | PC | 118 | qRT-PCR | median ratio | Clinical stage |
| Li 2017 | CRC | 24 | qRT-PCR | NA | LNM; gender; clinical stage |
| Tan 2017 | NSCLC | 80 | qRT-PCR | Youden index | LNM; gender; age; clinical stage |
NSCLC: Non-small cell lung cancer; CC: Cervical cancer; GC: Gastric cancer; HCC: Hepatocellular carcinoma; CRC: Colorectal cancer; OC: Ovarian cancer; PC: Prostate cancer; LNM: Lymph node metastasis; DM: Distant metastasis; NA: not available.